Akari Therapeutics' expenses had a significant negative impact on its revenue in Q3 2024, resulting in a net loss of $2.9 million. The company's total expenses for the period were not provided, but the negative net income indicates that the expenses exceeded the revenue generated during the quarter. This suggests that the company faced considerable costs that overshadowed any potential revenue, leading to a financial loss. The exact nature of these expenses is not detailed, but they clearly played a critical role in the company's financial performance during this period1.